By admin 
The landscape of pediatric oncology is poised for a significant shift as CureSearch for Children’s Cancer announces the recipient of its prestigious 2026 Catapult Award. Dr. Robbie Majzner, a renowned physician-scientist at the Dana-Farber Cancer Institute, has been awarded a $2 million investment to spearhead a Phase I clinical trial for a revolutionary Chimeric Antigen Receptor (CAR) T-cell therapy. This funding, co-sponsored by the Jeff Gordon Children’s Foundation, targets neuroblastoma, one of the most aggressive and difficult-to-treat solid tumors in children and young adults. By focusing on the critical juncture between laboratory discovery and clinical application, the Catapult Award aims to overcome the "valley of death" that often prevents promising pediatric treatments from reaching the bedside.
The Urgent Challenge of Relapsed Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It remains the most frequent extracranial solid tumor diagnosed in infancy and early childhood, accounting for approximately 7% to 10% of all pediatric cancers. Despite its relatively low incidence compared to adult cancers, its impact is disproportionately severe; neuroblastoma is responsible for more than 10% of all childhood cancer deaths.
For patients diagnosed with high-risk neuroblastoma, the current standard of care involves an intensive, multi-modal regimen including high-dose chemotherapy, surgical resection, radiation, and stem cell transplants. While these interventions can induce remission, the long-term survival rate for high-risk cases remains stubbornly below 50%. The prognosis becomes even more dire for children who experience a relapse or whose cancer is refractory to initial treatments. For these patients, conventional therapies often fail to provide a durable cure, leaving families with few options and a desperate need for innovation. Furthermore, the survivors of high-risk neuroblastoma often face a lifetime of chronic health issues, including hearing loss, cardiovascular complications, and secondary malignancies, stemming from the toxicity of current treatments.
The Evolution of CAR T-Cell Therapy in Solid Tumors
CAR T-cell therapy represents one of the most significant breakthroughs in modern oncology. The process involves harvesting a patient’s own T-cells—the "soldiers" of the immune system—and genetically engineering them to express a special receptor that recognizes a specific protein on the surface of cancer cells. Once infused back into the patient, these "living drugs" seek out and destroy the malignancy.
While CAR T-cell therapy has achieved remarkable, curative success in liquid cancers such as B-cell acute lymphoblastic leukemia (ALL), its application in solid tumors like neuroblastoma has been hampered by several biological hurdles. Unlike blood cancers, solid tumors create a hostile microenvironment that can suppress immune activity. Furthermore, solid tumors often lack unique markers, making it difficult to target cancer cells without damaging healthy tissue.
A primary obstacle identified by researchers is T-cell exhaustion. In the dense, immunosuppressive environment of a solid tumor, CAR T-cells often become "tired" or dysfunctional over time, losing their ability to proliferate and kill cancer cells. Dr. Majzner’s research specifically addresses this limitation, moving beyond first-generation CAR designs to create a more resilient immune response.
Technical Innovation: The ZAP70 Signaling Architecture
The clinical trial funded by the CureSearch Catapult Award focuses on a next-generation CAR T-cell designed to target GD2, a disialoganglioside highly expressed on the surface of neuroblastoma cells. While GD2 has long been a target for monoclonal antibody therapies, Dr. Majzner’s team has introduced a novel signaling protein called ZAP70 into the CAR architecture.
In a standard CAR T-cell, the signaling relies on a protein complex known as CD3-zeta. However, Dr. Majzner’s preclinical research suggested that by incorporating ZAP70—a kinase that plays a central role in natural T-cell signaling—the engineered cells could bypass some of the inhibitory signals that lead to exhaustion. This redesigned architecture allows the T-cells to maintain their activity for longer periods, essentially "recharging" them as they fight the tumor.
Preclinical data published leading up to this award demonstrated that these ZAP70-enhanced CAR T-cells showed superior anti-tumor activity in laboratory models compared to traditional GD2-targeted therapies. Crucially, the cells exhibited improved persistence, meaning they remained in the body longer to guard against recurrence, and showed signs of a more favorable safety profile, reducing the risk of "off-target" toxicity.
A Strategic Timeline: From Laboratory to Phase I Trials
The journey of this therapy follows a rigorous chronological path from discovery to the upcoming clinical implementation. Over the past several years, Dr. Majzner and his colleagues at Dana-Farber have conducted extensive in vitro and in vivo studies to validate the ZAP70 signaling concept. The selection for the 2026 Catapult Award marks the transition into the most critical phase of development.
- Discovery Phase (Prior to 2024): Identification of ZAP70 as a key modulator of T-cell persistence and the development of the GD2-targeted CAR construct.
- Preclinical Validation (2024-2025): Success in animal models demonstrating that the new CAR architecture could eradicate established neuroblastoma tumors where previous versions failed.
- Award Selection (Late 2025): CureSearch and the Jeff Gordon Children’s Foundation conduct a peer-reviewed evaluation of the proposal, selecting Dr. Majzner based on the potential for clinical impact and the scientific rigor of the data.
- Clinical Trial Launch (Expected 2026): The $2 million grant will facilitate the opening of a Phase I clinical trial. This stage focuses on determining the safety of the therapy in human subjects, establishing the optimal dosage, and observing early indicators of efficacy in children and young adults with relapsed or refractory neuroblastoma.
Institutional Support and Official Responses
The collaboration between CureSearch, the Jeff Gordon Children’s Foundation, and Dana-Farber Cancer Institute highlights the necessity of public-private partnerships in advancing pediatric medicine. Because the market for childhood cancer drugs is significantly smaller than that for adult cancers, pharmaceutical companies are often hesitant to invest in early-stage pediatric research. This makes philanthropic grants like the Catapult Award essential.
Dr. Robbie Majzner emphasized the transformative nature of this funding. "Current GD2 CAR T cells only work in patients with small amounts of disease," Majzner noted. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, reinforced the organization’s commitment to high-stakes research. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," Myers stated. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
Broader Impact and Future Implications for Oncology
The implications of Dr. Majzner’s Phase I trial extend far beyond neuroblastoma. If the ZAP70 signaling architecture proves successful in humans, it could provide a blueprint for treating other solid tumors that express the GD2 molecule, such as osteosarcoma (a common bone cancer in teenagers), melanoma, and certain types of brain tumors like Diffuse Intrinsic Pontine Glioma (DIPG).
Furthermore, the study contributes to the broader understanding of T-cell biology. By demonstrating how to engineer cells that resist exhaustion, this research could inform the development of CAR T-cell therapies for adult cancers, including lung, breast, and prostate cancers, which have similarly struggled with the immunosuppressive environments of solid tumors.
The Catapult Award’s focus on the Phase I trial stage is a strategic choice. By funding the initial human testing, CureSearch provides the "proof of concept" data required to attract larger-scale investment from the National Cancer Institute (NCI) or biopharmaceutical partners for Phase II and III trials. This "de-risking" of early-stage science is a critical component of the modern drug development pipeline.
Conclusion: A New Horizon for Pediatric Patients
The $2 million investment in Dr. Majzner’s research represents more than just a financial grant; it is a calculated bet on a scientific breakthrough that could redefine the prognosis for children with the most aggressive forms of cancer. As the 2026 trial approaches, the medical community remains cautiously optimistic that this next-generation CAR T-cell therapy will succeed where previous attempts have faltered.
By addressing the fundamental biological limitation of T-cell exhaustion and targeting a well-known marker of neuroblastoma with a sophisticated new tool, this research offers a beacon of hope for families who have exhausted all standard treatments. Through the continued support of organizations like CureSearch and the Jeff Gordon Children’s Foundation, the path from a laboratory bench at Dana-Farber to a life-saving treatment in a hospital room becomes significantly shorter.
